Momelotinib Dihydrochloride Monohydrate

Placeholder slot

(MOH-meh-LOH-tih-nib dy-HY-droh-KLOR-ide MAH-noh-HY-drayt)

This page contains brief information about momelotinib dihydrochloride monohydrate and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Ojjaara

FDA Approved

Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Momelotinib dihydrochloride monohydrate is approved to treat:

Myelofibrosis (a bone marrow disease) that is intermediate risk or high risk in adults with anemia, including the following types:
- Primary myelofibrosis.
- Post-polycythemia vera myelofibrosis.
- Post-essential thrombocythemia myelofibrosis.

Momelotinib dihydrochloride monohydrate is also being studied in the treatment of other types of cancer.

More About Momelotinib Dihydrochloride Monohydrate

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Research Results and Related Resources

Targeted Therapy to Treat Cancer

Clinical Trials Accepting Patients

Find Clinical Trials for Momelotinib Dihydrochloride Monohydrate - Check for trials from NCI's list of cancer clinical trials now accepting patients.